ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

UPB vs RNAC // DIVIDEND YIELD & FCF PAYOUT SAFETY

Upstream Bio Inc. (NASDAQ) VS. Cartesian Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: UPB 3 — RNAC 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UPB VS. RNAC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC UPB RNAC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 20.40% -65.00% +85.40 UPB /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 6.01 0.20 +5.81 UPB /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 UPB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 39.5 40.2 -0.70 RNAC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $183.5M $191.8M -$8.3M RNAC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR UPB REV RNAC REV UPB GROSS % RNAC GROSS % UPB FCF RNAC FCF
FY 2025 $2.9M $400.0K — — -$133.4M -$79.4M
FY 2024 $2.4M $38.3M — — -$59.7M -$32.8M
FY 2023 $2.4M $26.0M — — -$37.9M -$51.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UPB // BETA —
RNAC // BETA —